JP Morgan Chase
ALXO icon

JP Morgan Chase’s ALX Oncology ALXO Stock Holding History

JP Morgan Chase’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.3M Buy
1,044,728
+1,044,629
+1,055,181% +$1.87M ﹤0.01% 4092
2026
Q1 		$189 Hold
99
– – ﹤0.01% 7256
2025
Q4 		$112 Sell
99
-61,800
-100% -$93.6K ﹤0.01% 7201
2025
Q3 		$113K Sell
61,899
-26,453
-30% -$22.9K ﹤0.01% 5832
2025
Q2 		$36.7K Sell
88,352
-269,605
-75% -$136K ﹤0.01% 6023
2025
Q1 		$223K Buy
357,957
+121,911
+52% +$146K ﹤0.01% 5198
2024
Q4 		$394K Buy
236,046
+195,112
+477% +$300K ﹤0.01% 5160
2024
Q3 		$74.5K Buy
40,934
+509
+1% +$1.89K ﹤0.01% 5826
2024
Q2 		$244K Sell
40,425
-1,472
-4% -$18.1K ﹤0.01% 5062
2024
Q1 		$467K Sell
41,897
-5,686
-12% -$79.9K ﹤0.01% 4840
2023
Q4 		$709K Buy
47,583
+25,848
+119% +$245K ﹤0.01% 4557
2023
Q3 		$104K Buy
21,735
+3,179
+17% +$17.2K ﹤0.01% 5449
2023
Q2 		$139K Buy
18,556
+749
+4% +$4.9K ﹤0.01% 5293
2023
Q1 		$81K Buy
17,807
+4,391
+33% +$33.3K ﹤0.01% 5517
2022
Q4 		$151K Sell
13,416
-1,165
-8% -$13.1K ﹤0.01% 5176
2022
Q3 		$140K Buy
14,581
+1,153
+9% +$13.4K ﹤0.01% 5125
2022
Q2 		$109K Sell
13,428
-5,809
-30% -$63.3K ﹤0.01% 5362
2022
Q1 		$326K Buy
19,237
+3,417
+22% +$58.3K ﹤0.01% 4941
2021
Q4 		$340K Buy
15,820
+792
+5% +$34.2K ﹤0.01% 5054
2021
Q3 		$1.11M Buy
15,028
+2,683
+22% +$179K ﹤0.01% 4234
2021
Q2 		$675K Buy
12,345
+2,413
+24% +$144K ﹤0.01% 4520
2021
Q1 		$732K Buy
9,932
+4,838
+95% +$381K ﹤0.01% 4439
2020
Q4 		$439K Buy
5,094
+1,526
+43% +$91.8K ﹤0.01% 4441
2020
Q3 		$137K Buy
+3,568
New +$140K ﹤0.01% 4560

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

JP Morgan Chase's ALXO Position: Q2 2026 in Review

JP Morgan Chase increased its ALX Oncology (ALXO) stake by 1,055,181% in Q2 2026, buying an estimated $1.87M and bringing the position to 1,044,728 shares worth $2.3M. The position accounts for ﹤0.01% of the portfolio, ranked #4092.

JP Morgan Chase first reported a position in ALXO in Q3 2020 and has held it in 24 quarters since. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • JP Morgan Chase held 1,044,728 shares of ALX Oncology worth $2.3M as of Q2 2026.
  • JP Morgan Chase bought 1,044,629 ALX Oncology shares in Q2 2026, an estimated $1.87M.
  • ALX Oncology made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4092 holding.
  • JP Morgan Chase first reported a position in ALX Oncology in Q3 2020 and has held it in 24 quarters since.
  • 94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.